F-star Therapeutics, Inc. (NASDAQ:FSTX – Get Rating) – Equities research analysts at Oppenheimer boosted their Q2 2022 earnings per share (EPS) estimates for F-star Therapeutics in a research report issued to clients and investors on Wednesday, May 11th. Oppenheimer analyst H. Singh now forecasts that the company will post earnings per share of ($0.51) for the quarter, up from their previous forecast of ($0.66). Oppenheimer also issued estimates for F-star Therapeutics’ Q3 2022 earnings at ($0.59) EPS, Q4 2022 earnings at ($0.41) EPS, FY2022 earnings at ($2.04) EPS, FY2023 earnings at ($2.73) EPS, FY2024 earnings at ($2.50) EPS, FY2025 earnings at ($2.76) EPS and FY2026 earnings at ($0.36) EPS.
Other analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of F-star Therapeutics in a research note on Thursday, March 17th. Zacks Investment Research raised shares of F-star Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $25.21.
A number of large investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new position in F-star Therapeutics in the 4th quarter valued at about $29,000. JPMorgan Chase & Co. bought a new position in F-star Therapeutics in the 4th quarter valued at about $42,000. Envestnet Asset Management Inc. bought a new position in F-star Therapeutics in the 1st quarter valued at about $48,000. Morgan Stanley increased its holdings in F-star Therapeutics by 65.0% in the 2nd quarter. Morgan Stanley now owns 7,868 shares of the company’s stock valued at $68,000 after buying an additional 3,100 shares during the period. Finally, Millennium Management LLC bought a new position in F-star Therapeutics in the 3rd quarter valued at about $114,000. 51.67% of the stock is currently owned by institutional investors and hedge funds.
About F-star Therapeutics (Get Rating)
F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.
- Get a free copy of the StockNews.com research report on F-star Therapeutics (FSTX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for F-star Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for F-star Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.